Ultragenyx Pharmaceutical Inc.RARE
Market cap
$3.2B
P/E ratio
| 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Depreciation & amortization | 1 | 1 | 3 | 6 | 20 | 9 | 12 | 13 | 18 | 26 | 36 |
| Stock-based compensation | 5 | 25 | 48 | 68 | 80 | 82 | - | - | - | - | - |
| Cash from operations | -45 | -106 | -161 | -254 | -291 | -345 | -132 | -339 | -380 | -475 | -414 |
| Capital expenditures | -2 | -5 | -10 | -3 | -4 | -25 | -44 | -73 | -116 | -44 | -7 |
| Cash from investing | -123 | -292 | 90 | 56 | -33 | -13 | -179 | -195 | -292 | 168 | -18 |
| Cash from financing | 185 | 468 | 139 | 136 | 337 | 679 | 600 | 119 | 501 | 388 | 399 |
| Free cash flow | |||||||||||
| FCF margin (%) | - | - |